The incidence of hepatocellular carcinoma (HCC) is rising in the United States and it is projected to continue to increase over the next decade. This session will highlight recent advances in research in hepatocellular cancer and will include speakers on genomic profiling of liver cancers, utilization of molecular data for diagnosis, classification and therapy, and therapeutic trials. Genomic profiling has led to the identification of molecular tools that may change our way of classifying and predicting the behavior of liver tumors. The use of genotype and phenotype associated signatures to refine diagnosis, prognosis, and treatment of liver tumors will be discussed along with novel applications of molecular tools for diagnostic and therapeutic use. The integration of genetic and phenotypic data with preclinical drug development, and early phase clinical trials will illustrate new avenues to translate advances in molecular characterization and pathogenesis into clinical practice. This session will appeal to clinical and translational scientists, cancer geneticists and investigators interested in therapeutic aspects of HCC.
New Concepts in Organ Site Research: Recent Advances in Hepatocellular Cancer: From Molecular Profiling to Therapeutics

Molecular targeted therapies in HCC; Tanios Bekaii-Saab. The Ohio State University, Columbus, OH

Molecular profiling - insights into the pathogenesis of HCC; Xin Wei Wang. National Institutes of Health, NCI, Bethesda, MD

Genomic markers in liver tumors- translating molecular markers to clinical utility; Jessica Zucman-Rossi. Inserm U-674, Paris, France

Phenotype-based targeting therapies in HCC; Tushar Patel. The Ohio State University, Temple, TX,